NDA Submission Completed for Zipalertinib + Chemo in 1L EGFR Exon 20 Ins Mutation NSCLC November 18, 2026
CRL Received from FDA for BLA Application Based on HARMONi Study of ivonescimab + platinum-containing chemo for EGFR TKI-treated NSCLC patients November 18, 2026
Positive Updated Silevertinib Ph 2 Results Announced with FDA Feedback for Potential Registration path in 1L EGFR-NCM NSCLC November 18, 2026
Not Approvable Letter received from the FDA in response to PMA application for Optune Mya® in NSCLC patients with brain mets following stereotactic radiation November 18, 2026
Outcome from the End-of-Phase 1 Meeting with the FDA and Pivotal Ph 2 Trial Design for OMNI-EGFR™ Inhibitor, BH-30643, in EGFR C797S-Positive NSCLC Announced November 11, 2026
Ph 1/2 Study of Vopimetostat in Combination with ERAS-0015 Initiated in patients with MTAP-deleted pancreatic cancer and MTAP-deleted/RAS mutant NSCLC November 11, 2026
Ph 2 Study of Ivonescimab in the Perioperative Setting for Resectable NSCLC Published in Nature Medicine November 11, 2026
Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan November 11, 2026
Updated results from Cohorts 1 and 2 of Ph 2 IOV-LUN-202 trial in previously treated non-squamous mNSCLC announced November 4, 2026
Additional Positive Results of Combi-TED Ph 2 Trial with Tedopi® (OSE2101) in metastatic NSCLC Announced November 4, 2026
First Patient dosed in Ph 3 RASolve 308 Trial of Zoldonrasib + Pembrolizumab and Chemo in 1L Metastatic RAS G12D Non-Squamous NSCLC October 28, 2026
First Patients enrolled in Standard of Care Chemo Combination Cohorts of Global Ph 1/2 ASCEND Trial of CR-001 October 28, 2026
VS-7375 Demonstrates 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed) October 20, 2026
Data from FURTHER Ph 1b (FURMO-002) of firmonertinib in 1L EGFR PACC-mutant NSCLC published in Cancer Cell October 20, 2026
Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the US FDA for CRC and NSCLC October 14, 2026
FAILED TRIAL: FURVENT Ph 3 trial of firmonertinib monotherapy in NSCLC patients with EGFR exon 20 insertion mutations did not meet primary PFS endpoint by BICR October 14, 2026
FDA Grants Fast Track Designation for TRE-515 in Combination with KRAS G12C Inhibitors for the Treatment of NSCLC October 6, 2026
NDA Submission Initiated for Zipalertinib + Chemo in 1L EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program October 6, 2026
New Analyses Reinforcing Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC Announced September 22, 2026